Press & Media Coverage
Catch up on our latest press coverage
[White Paper] Molecular Imaging: Changing the Way We Look at Cancer
Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
2023 AGM Resolution Overview
Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting
Imagion initiates leadership restructuring plan
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the
Quarterly Activity Report and Appendix 4C for 31 March 2023
https://youtu.be/8MSNhYapsRI Highlights: Reported positive results of independent review of utility for MagSense® HER2 breast cancer detection Announced plan to advance MagSense® HER2 program to multi-site
Notice of 2022 Annual General Meeting and Proxy Form
In accordance with Listing Rule 3.17, Imagion Biosystems Limited attaches a copy of the following documents: 1. Letter to Shareholders regarding arrangements for the Annual
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.